standard anti-tuberculosis agents
PreclinicalSmall molecule
standard anti-tuberculosis agents is one of 24 small molecule programs targeting Peptic ulcer. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
28 competitors in Peptic Ulcer
#DrugCompanyPhaseTrials
1Prevacid
TakedaApproved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Bayer Aspirin
BayerApproved
Protonix
WWyeth-Lederle Vaccines
Approved
Dexilant
TakedaApproved
Cytotec
PfizerApproved
Takecab
PPhathom Pharmaceuticals, Inc.
Approved
Aciphex
Akero TherapeuticsApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Advil
KKenvue Brands
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details